Subscribe
We deliver the northeast

Will PM Narendra Modi be quarantine for 2 weeks upon arrival in USA?

NEW DELHI: Covaxin, Bharat Biotech’s India-made vaccine against the COVID-19 disease, has not yet been approved for use in the United States neither by the country’s top public health regulator — the Food and Drug Administration (FDA) nor the World Health Organisation (WHO).

However, crores of Indians have been administered with both the doses of Covaxin, including Prime minister Narendra Modi.

White House COVID-19 coordinator Jeff Zients recently announced that Non-US citizens will finally be allowed into the country if they have been administered with both the doses of COVID-19 vaccine. Travellers will also have to show negative COVID test result. It was also mentioned that fully vaccinated passengers will not be required to quarantine.

Now, question is- Will PM Narendra Modi be quarantine upon his arrival tonight in the USA?

The question arises because Covaxin is still not yet approved by the country and hence the doses might be considered invalid leading to 2 weeks of quarantine of the PM.

ALSO READ: Assam: As many as 24 arrested in Dhubri for illegal land trade

Raising the topic Anand Ranganathan tweeted, “The USA has still not approved our Covaxin through either its FDA or CDC, and neither has the WHO. Does this mean that PM
@narendramodi, vaccinated with Covaxin, will be quarantined for 2 weeks upon his arrival tonight in the USA? He should be. He should suffer like all Indians.”

Prime Minister Narendra Modi, leaving for his three-day visit to the US this morning, called it an “occasion to strengthen our strategic partnership with the US and consolidate ties with Japan and Australia.”
The Prime Minister will participate in the first in-person summit of Quad leaders, address the United Nations General Assembly and also meet with Joe Biden for the first time since his election as US President.

Meanwhile, the Phase 2/3 trials of Bharat Biotech’s Covaxin for use in children under 18 years of age, are complete, the firm’s Managing Director (MD) Krishna Ella said on Tuesday.

He added that Bharat Biotech will share all relevant data pertaining to the trials with the Drugs Controller General of India (DCGI) by next week.

Support our brand of fearless and investigative journalism:

Support us

Download InsideNE App

Follow us on Facebook

Leave A Reply